DGAP-News: Press Release: 4SC to present at World Epigenetics Summit clinical development programme with lead cancer drug Resminostat
(firmenpresse) - DGAP-News: 4SC AG / Key word(s): Miscellaneous
Press Release: 4SC to present at World Epigenetics Summit clinical
development programme with lead cancer drug Resminostat
06.12.2011 / 07:30
---------------------------------------------------------------------
Press Release
4SC to present clinical development programme with lead cancer drug
Resminostat at World Epigenetics Summit
Planegg-Martinsried, Germany, 6 December 2011 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for autoimmune diseases and cancer, today announced that the
company will present the clinical Phase II programme with its lead
anti-cancer compound resminostat at the 2nd World Epigentics Summit from
6-8 December 2011 in Munich. Dr. Bernd Hentsch, 4SC's Chief Development
Officer, will give the oral presentation on 8 December 2011 at 4:15 pm
(CET).
Resminostat is an oral pan-histone-deacetylase (HDAC) inhibitor which, as a
novel targeted cancer therapeutic, is designed to cause differentiation of
tumour cells and programmed cell death (apoptosis) by modifying tumour
cells' DNA structure. Resminostat is currently being clinically developed
in three different cancer indications: hepatocellular carcinoma (HCC),
which is the most common type of liver cancer, colorectal cancer (CRC), and
Hodgkin's lymphoma (HL), a cancer of the lymphatic system. The compound has
shown a very good safety profile and promising anti-tumour activity in
pre-clinical and clinical development up to clinical Phase II trials.
After recently having published positive data from a Phase II study with
resminostat in HL patients, 4SC expects to publish results of a Phase II
study with resminostat in HCC at the beginning of 2012. Currently the
company is preparing for discussions of the next development steps with
regulatory authorities and potential partners, which - considering the high
medical need and the limited therapeutic options available in the cancer
indications addressed with resminostat - is expected to be a pivotal
development programme.
From 8 December 2011, 4:15 pm (CET), the detailed presentation of Dr.
Hentsch at the World Epigentics Summit will be available for download at
http://www.4sc.de/product-pipeline/publications-posters/resminostat.
Ends
About Resminostat
Resminostat (4SC-201) is an oral pan-histone-deacetylase (HDAC) inhibitor.
HDAC inhibitors modify the DNA structure of tumour cells to cause their
differentiation and programmed cell death (apoptosis) and are therefore
considered to offer a mechanism of action that has the particular potential
to halt tumour progression and induce tumour regression. Resminostat is
currently being investigated in the Phase II SHELTER study as a second-line
treatment for advanced hepatocellular carcinoma (HCC) and in the Phase I/II
SHORE study as a second-line treatment in colorectal cancer in KRAS-mutant
patients. The Phase II SHELTER study is expected to report results in the
beginning of 2012. Initial results of the SHORE study are expected in 2012.
With an overall response rate of 35.3% and a clinical benefit in 55.9% of
the patients, the Phase II SAPHIRE trial with resminostat as a monotherapy
in advanced Hodgkin's lymphoma has demonstrated the drug's substantial
anti-tumour activity in a heavily pre-treated patient population together
with very good safety and tolerability. The study is still ongoing as one
further patient is still continuing therapy and has currently achieved
stabilization of disease for more than 30 weeks in the optional follow-up
phase beyond the study's main treatment part of 12 weeks.
About 4SC
4SC (ISIN DE0005753818) discovers and develops targeted small-molecule
drugs for the treatment of diseases with a high unmet medical need in
various autoimmune and cancer indications. These drugs are intended to
provide patients with innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The company's balanced pipeline comprises promising products that are
in various stages of clinical development. 4SC's aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
leading pharmaceutical companies. Founded in 1997, 4SC currently has 94
employees and has been listed on the Prime Standard of the Frankfurt Stock
Exchange since December 2005.
Legal Note
This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.
For more information please visit www.4sc.com or contact:
4SC AG
Jochen Orlowski, Investor Relations&Public Relations
jochen.orlowski(at)4sc.com, Tel.: +49 (0) 89 70 07 63 66
Bettina v. Klitzing-Stückle, Corporate Communications
bettina.von.klitzing(at)4sc.com, Tel.: +49 (0) 89 70 07 63 0
MC Services (Europe)
Raimund Gabriel
raimund.gabriel(at)mc-services.eu, Tel.: +49 (0) 89 21 02 28 30
Mareike Mohr
mareike.mohr(at)mc-services.eu, Tel.: +49 (0) 89 21 02 28 40
The Trout Group (USA)
Chad Rubin
Crubin(at)troutgroup.com, Tel.: +1 646 378 2947
End of Corporate News
---------------------------------------------------------------------
06.12.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public(at)4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
148461 06.12.2011
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.12.2011 - 01:30 Uhr
Sprache: Deutsch
News-ID 1063312
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 347 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Press Release: 4SC to present at World Epigenetics Summit clinical development programme with lead cancer drug Resminostat
"
steht unter der journalistisch-redaktionellen Verantwortung von
4SC AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
